Plain-English translation of NCT04546399 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study compares two treatment approaches for children and young adults with relapsed B-cell acute lymphoblastic leukemia (a blood cancer). Some participants will receive alone, while others will receive combined with , a medication that helps the immune system fight cancer cells. The trial aims to see which approach helps patients stay cancer-free longer.
When leukemia comes back after initial treatment, it becomes much harder to treat and patients face a poorer prognosis. This medication combination has shown promise in early studies, and researchers want to know if adding to can improve survival and give patients better chances of long-term remission.
You likely qualify if…
You likely don't qualify if…
You will receive immunotherapy medications through an IV (intravenous line), with given as a continuous infusion over 28 days per cycle. Depending on which treatment group you are assigned to, you may also receive and other supportive medications like . You will have regular blood tests, bone marrow biopsies, spinal taps (lumbar punctures), and imaging scans to monitor how well the treatment is working and check for any side effects. Treatment typically involves up to 2 cycles of therapy, each lasting about 37 days, though your doctor may decide to stop earlier if the cancer is no longer detected.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States